Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017 (2017), Article ID 5831682, 7 pages
Research Article

Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

1University Eye Hospital, Hanover Medical School, Hanover, Germany
2Eye Center, University Hospital Freiburg, Freiburg, Germany

Correspondence should be addressed to Amelie Pielen

Received 13 April 2017; Accepted 28 June 2017; Published 30 July 2017

Academic Editor: Michael J. Koss

Copyright © 2017 Amelie Pielen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate the anatomical and functional outcome of intravitreal dexamethasone implant for macular edema secondary to central (C) or branch (B) retinal vein occlusion (RVO) in patients with persistent macular edema (ME) refractory to intravitreal antivascular endothelial growth factor (VEGF) treatment compared to treatment naïve patients and to dexamethasone-refractory eyes switched to anti-VEGF. Methods. Retrospective, observational study including 30 eyes previously treated with anti-VEGF (8 CRVO, 22 BRVO, mean age 69 ± 10 yrs), compared to 11 treatment naïve eyes (6 CRVO, 5 BRVO, 73 ± 11 yrs) and compared to dexamethasone nonresponders (2 CRVO, 4 BRVO, 69 ± 12). Outcome parameters were change in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) measured by spectral-domain optical coherence tomography. Results. Mean BCVA improvement after switch to dexamethasone implant was 4 letters (), and treatment naïve eyes gained 10 letters (), while we noted no change in eyes after switch to anti-VEGF (). Median CFT decrease was most pronounced in treatment naïve patients (−437 μm, ) compared to anti-VEGF refractory eyes (−170 μm, ) and dexamethasone-refractory eyes (−157, ). Conclusions. Dexamethasone significantly reduced ME secondary to RVO refractory to anti-VEGF. Functional gain was limited compared to treatment naïve eyes, probably due to worse BCVA and CFT at baseline in treatment naïve eyes.